Skip to content

â?? Role of Markatbija churn on Respiratory Rate in Tamak Shvasa with special reference to Bronchial Asthmaâ??

â??A Randomised Control Trial on Markatbija churn in Tamak Shvas with special reference to Bronchial Asthmaâ??

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/040712
Enrollment
60
Registered
2022-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma Health Condition 2: J454- Moderate persistent asthma

Interventions

Intervention1: Markatbija Churn: Markatbija churn 5gm bd with 10ml ghrit before meal for 30 days Control Intervention1: Tablet Deriphylline Retard: Deriphylline Retard 150mg TDS with water orally fo

Sponsors

Government ayurved college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient of Tamak Shvasa presenting the clinical features highlighted in classical literature will be randomly irrespective of sex , caste , religion and socio economical status. 2. Patient of Tamak Shvasa ageing in between 16 to 60 years will be considered. 3. Patient from mild to moderate exacerbation of bronchial asthma. 4. Positive test of reversibility- a) symptomatic patients- An improvement of 60 L / min or > 20 % in PEFR 10 min after inhalation of bronchodilator ( salbutamol ) . b) Asymptomatic patient 60 L / min or > 20 % fall in PEFR by provocation with physical exercise ( brisk walking for 5-10 min ) followed by reversal upon in Inhalation of bronchodilator ( salbutamol) when assessed after 10 min . 6. Heemoglobin >10 gm%. 7. Patient willing and able to participate for 4 weeks. 8. Patient showing symptoms, signs and medical history of bronchial asthma will be included.

Exclusion criteria

Exclusion criteria: Patient with active lung disease, patient with lung disease other than bronchial asthma, patient who had major surgeries within 2 weeks prior to screening visited , patient with evidence of malignancy, patient with severe asthma exacerbation, pregnant or lactating , patient with poorly controlled hypertension ( >160/100 mmhg) , patient with uncontrolled diabetes mellitus ( blood sugar fasting >130 mg /dl and post meal 250 mg /dl )

Design outcomes

Primary

MeasureTime frame
1.To evaluate the efficacy of markatbija churn in management of Tamak Shvasa specifically on respiratory rate , peak exploratory flow rate, sustained maximum inspiration and MRC dyspnoea scale. 2. To study the effect of Deriphylline retard in the management of Tamak Shvasa specifically on respiratory rate , peak expiratory flow rate, sustained maximal inspiration and MRC dyspnoea scale. 3. To compare the effect of markatbija churn with tablet Deriphylline retard with respect to respiratory rate , peak expiratory flow rate , sustained maximal inspiration and MRC dyspnoea scale.Timepoint: 18 months

Secondary

MeasureTime frame
1.To study Tamak Shvasa in detail from Ayurvedic perspective. 2. To study bronchial asthma with modern point of view.Timepoint: 18 months

Countries

India

Contacts

Public ContactJayant D GUlhane

Government ayurved college and hospital ,Nagpur

Jayant.gulhane.62.6@gmail.com9511828972

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026